TheraPPI completes a first closing of Pre-Seed Financing to advance its lead oncology program targeting a novel protein interaction

In addition to non-dilutive financing from BPI France and FONGIT (Switzerland), TheraPPI completes an initial equity financing to advance the development of its lead program targeting ERK/MyD88 interaction, a novel drug target discovered by TheraPPI founders

Patricia Delaite joins the company as Chairwoman of the Board of Directors. John Tchelingerian and Barthélemy Helg join the Board as Independent Directors

February 9, 2025 – Lyon, France and Geneva Switzerland

TheraPPI Bioscience (“TheraPPI”), a preclinical biotechnology company focused on developing small molecules that modify protein interactions, announced today the first closing of its Pre-Seed financing. All new investors have substantial experience in the biotech sector.

TheraPPI will use the proceeds today’s announced to advance the development of its lead program targeting ERK/MyD88, a novel protein interaction in the Ras-MAPK pathway to tackle cancer drug resistance and to offer more effective and safer therapies to patients with advanced cancers.

TheraPPI also announced the inception of TheraPPI Bioscience SA (Geneva, Switzerland) and the nomination of a Board of Directors of this new company. Patricia Delaite, MD, a clinical oncologist and executive in biotech companies, joins the company’s Board as Chairwoman. John Tchelingerian, PhD, a serial entrepreneur and private investor in the biotech sector, and Barthélemy Helg, LL. M. & MBA, an executive in the biotech and food tech sectors, join the company’s Board as independent Directors. Luc Otten, MD, PhD, founder CEO, and Toufic Renno, PhD, founder CSO of TheraPPI, are also Board Directors.

“TheraPPI is developing a first-in-class drug for bringing efficacious therapy to patients with cancer who can’t any longer benefit from modern targeted therapies or immunotherapies. TheraPPI’s lead program tackles a real unmet medical need by fighting cancer drug resistance, a major cause of death. I am deeply honored to support TheraPPI on this exciting journey” declared Patricia Delaite. “Thanks to the support of our new investors, our Board of Directors and this open Pre-Seed financing round, we are moving forward by expediting TheraPPI’s lead program and preparing additional developments. The combination of long experiences in both academia and industry from the team with a strong corporate governance provides a solid foundation for future TheraPPI successes,” added Luc Otten.

…